Compliance with desired practice (measured on a continuous scale) · health personnel
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient outcomes · health personnel
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Compliance with desired practice (Yes/No ‐ dichotomous outcomes) · health personnel
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Median · health personnel
1 finding from 1 review
Depression response or remission (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · women of any age, with PND up to 12 months
Antidepressants may leads to lower adverse events compared with psychological interventions (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes treatment acceptability ‐ dropouts compared with psychological interventions (very low certainty).
1 finding from 1 review
RR 1.07 [0.24, 4.88]
Studies not reported
Very low
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression response or remission (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes treatment acceptability ‐ dropouts compared with psychosocial interventions (very low certainty).
1 finding from 1 review
RR 1.94 [1.12, 3.35]
Studies not reported
Very low
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), fotemustine…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review
Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), BEV + irinotecan…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review